Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Little, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Little, M.
Related Collections
Right arrow Environment and Disease
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 68:259-275 (2003)
© 2003 Oxford University Press

Risks associated with ionizing radiation

Environmental pollution and health

MP Little

Department of Epidemiology and Public Health, Imperial College Faculty of Medicine, St Mary’s Campus, London, UK

Correspondence to: Dr MP Little, Department of Epidemiology and Public Health, Imperial College Faculty of Medicine, St Mary’s Campus, Norfolk Place, London W2 1PG, UK. E-mail: mark.little{at}imperial.ac.uk


   Abstract
Top
 Abstract
Introduction
 Types of ionizing radiation,...
 Health effects
 Key points for clinical...
 Acknowledgements
 References
 
This paper reviews current knowledge on the deterministic and stochastic risks (the latter including the risk of cancer and of hereditary disease) associated with exposure to ionizing radiation. Particular attention is paid to cancer risks following exposure to man-made low linear energy transfer radiation. Excess cancer risks have been observed in the Japanese atomic bomb survivors and in many medically and occupationally exposed groups. In general, the relative risks among Japanese survivors of atomic-bomb explosions are greater than those among comparable subsets in studies of medically exposed individuals. Cell sterilization largely accounts for the discrepancy in relative risks between these two populations, although other factors may contribute, such as the generally higher underlying cancer risks in the medical series than in the Japanese atomic bomb survivors. Risks among occupationally exposed groups such as nuclear workforces and underground miners are generally consistent with those observed in the Japanese atomic bomb survivors.


   Introduction
Top
 Abstract
 Introduction
Types of ionizing radiation,...
 Health effects
 Key points for clinical...
 Acknowledgements
 References
 
Risks associated with ionizing radiation have been known for almost as long as ionizing radiation itself: within a year of the discovery of X-rays by Röntgen, skin burns had been reported1,Go2Go and within 7 years a case of skin cancer was observed3Go, in all cases associated with high dose X-ray exposure. In general, risks associated with ionizing radiation can be divided into the so-called stochastic effects (genetic risks in offspring, somatic effects (cancer) in directly exposed population), and deterministic effects. This review summarizes the stochastic and the deterministic risks associated with exposure to radiation.


   Types of ionizing radiation, sources of exposure, units
Top
 Abstract
 Introduction
 Types of ionizing radiation,...
Health effects
 Key points for clinical...
 Acknowledgements
 References
 
Ionizing radiation is any electromagnetic wave or particle that can ionize, that is remove an electron from, an atom or molecule of the medium through which it propagates. The process of ionization in living material necessarily changes atoms and molecules, at least transiently, and may thus damage cells. If cellular damage occurs and is not adequately repaired, the cell may not survive, reproduce or perform its normal function. Alternatively, it may result in a viable but modified cell, which may go on to become cancerous if it is a somatic cell, or lead to inherited disease if it is a germ cell.

The basic quantity used to measure absorbed dose from ionizing radiation is the gray (Gy), defined as 1 J of initial energy (of charged particles released by the ionization events) per kg of tissue4Go. The biological effects per unit of absorbed dose differ with the type of radiation and the part of the body exposed, so that a weighted quantity called the effective dose is used, for which the measure is the sievert (Sv)4Go. Low linear energy transfer (LET) radiation (photons, electrons, muons) is assigned a radiation weighting factor of 1, whereas high LET radiation (neutrons, protons, {alpha}-particles) is assigned radiation weighting factors of between 5 and 20, depending on the energy of the particles5Go. A related concept is that of relative biological effectiveness (RBE) of a given dose Dq of some specified type ‘q’ of radiation, which is defined as RBEq(Dq) = Dr/Dq where Dr is the dose of the reference radiation (usually X-rays or gamma rays) required to produce the same biological effect6,Go7Go. Since it is a ratio of doses it is a scalar quantity, without units.

All living organisms are continually exposed to ionizing radiation, for example from cosmic and terrestrial gamma rays, ingestion of potassium-40 and radon exposure. Worldwide, the average human exposure to radiation from natural sources is 2.4 mSv per year, about half of which is due to the effects of radon daughters4Go. Diagnostic medical exposures add about 0.4 mSv per year to this figure, atmospheric nuclear testing about 0.005 mSv per year, the Chernobyl accident 0.002 mSv per year, and nuclear power production about 0.0002 mSv per year4Go. Further details on the typical range of these figures, and how they have changed over time, are given in Table 1. These figures should be compared with the average colon dose of 0.2 Sv, and a maximum in excess of 5 Sv, that the proximally exposed groups received in the Japanese atomic bomb survivors Life Span Study (LSS) cohort8Go.


View this table:
[in this window]
[in a new window]
  		Table 1 Current sources of exposure, annual effective doses (mSv/year) and typical ranges (taken from Ref. 4)

 


   Health effects
Top
 Abstract
 Introduction
 Types of ionizing radiation,...
 Health effects
Key points for clinical...
 Acknowledgements
 References
 
Deterministic effects

Deterministic effects generally occur only after high-dose acute exposure (mostly >0.1 Gy, see Table 2) and are characterized by non-linear dose–responses, with a threshold dose below which the effect is not observed. Because of these features, deterministic effects are of most relevance in radiotherapy; normal tissue therapy doses are limited to avoid these effects. Deterministic effects are thought to arise from the killing of large groups of cells in the tissues concerned, leading to functional deterioration in the organs affected. Deterministic effects generally arise within days (e.g. prodromal syndrome, gastrointestinal syndrome, central nervous system syndrome) or weeks (e.g. haematopoietic syndrome, pulmonary syndrome) of exposure; however, certain deterministic effects (e.g. cataracts, hypothyroidism) are manifest only over periods of years or more9Go. Most of the information on deterministic effects of radiation comes from (a) medically exposed groups, (b) the survivors of the atomic bombings of Hiroshima and Nagasaki, (c) radiation accidents and (d) animal experiments9Go. The probability, P, of most deterministic effects following an acute dose, D, is given by a modified Weibull distribution:

where V is the shape factor, determining the steepness of the risk function, and T is the threshold dose below which no effect is observed9,Go10Go. D50 (>T) is the risk at which the effect is expected to be observed in half the population, and is a function of the radiation dose rate DR (in Gy h–1)9Go:

Values of the parameters are given in Table 2. The International Commission on Radiological Protection (ICRP)5Go recommends that generally lower RBEs for high LET radiation be used for most deterministic effects than for stochastic effects, as indicated in Table 2.


View this table:
[in this window]
[in a new window]
  		Table 2 Recommended parameters for use in equations (1)–(2) for fatal and non-fatal deterministic effects (taken from Ref. 9)

 

Although equation (1) is thought to describe most deterministic effects, there are certain effects for which it does not apply. Particularly problematic in this respect are severe mental retardation and reduction in IQ following irradiation of the fetus. Otake et al11Go and Otake and Schull12Go observed a dose-related increase in severe mental retardation in those exposed in utero as a result of the atomic bomb explosions in Hiroshima and Nagasaki. This was particularly marked for those exposed in the period 8–15 weeks post-conception. A threshold in the region of 0.1–0.3 Gy was indicated11,Go12Go. There was a linear reduction in IQ with increasing uterine dose in the atomic bomb survivors, although thresholds of at least 0.1 Gy are consistent with the data12Go.

Stochastic effects

Stochastic effects are the main late health effects that are expected to occur in populations exposed to ionizing radiation; somatic risks dominate the overall estimate of health detriment. For both somatic and genetic effects the probability of their occurrence, but not their severity, is taken to depend on the radiation dose. The dose–response may be non-linear, as for deterministic effects. However, in contrast to the situation for deterministic effects, for most stochastic effects it is generally accepted that at sufficiently low doses there is a non-zero linear component to the dose–response i.e. there is no threshold. There is little evidence, epidemiological13–GoGo15Go or biological16Go, for thresholds for stochastic effects.

Heritable genetic effects
 The heritable genetic risks associated with radiation exposure are estimated directly from animal studies in combination with data on baseline incidence of disease in human populations17Go. There are no usable human data on radiation-induced germ cell mutations, let alone induced genetic diseases, and the results of the largest and most comprehensive of human epidemiological studies, namely that carried out on the children of the Japanese atomic bomb survivors, are negative; there are no statistically significant radiation-associated adverse hereditary effects in this cohort18Go. The data on the induction of germline mutations at human minisatellite loci19,Go20Go, although of importance from the standpoint of direct demonstration of radiation-induced heritable genetic changes in humans, are not suitable for risk estimation, because they occur in non-coding DNA and are not associated with heritable disease17Go.

Simple linear models of dose are generally employed to model genetic effects. For example, the preferred risk model used in the 2001 report of the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR)17Go assumes that the excess heritable genetic risk for disease class i associated with a dose D of radiation to the parental gonads is given by:

where Pi is the baseline incidence of that disease class, MCi is the mutational component of the disease class [defined as the relative increase in disease frequency (relative to the baseline) per unit relative increase in mutation rate (relative to the spontaneous rate)], PCRFi is the potential recoverability correction factor for the disease class (the fraction of induced mutations compatible with live births) and DDi is the mutational doubling dose (i.e. the dose required to double the mutational load associated with the disease). Table 3 summarizes estimates of risk for the first- and second-generation progeny of an irradiated population that has sustained radiation exposure in the parental generation and no radiation subsequently. These risk estimates assume a mutational doubling dose, DDi, of 1 Gy, that is based on human data on spontaneous mutation rates and mouse data on induced mutation rates17Go. Neel et al18Go derived an estimate of the doubling dose in the atomic bomb survivors of 3.4–4.5 Sv, based on examination of a combination of five endpoints. However, as discussed by UNSCEAR17Go, in view of the differences between the endpoints considered by Neel et al18Go and those employed by UNSCEAR17Go, and the uncertainties in the estimates of Neel et al18Go, their estimate of the doubling dose is entirely compatible with that used by UNSCEAR17Go.


View this table:
[in this window]
[in a new window]
  		Table 3 Cancer and heritable genetic risk estimates associated with low dose irradiation (taken from Refs 16 and 17)

 

Somatic effects (cancer)
 Most of the information on radiation-induced cancer risk comes from (a) the Japanese atomic bomb survivors, (b) medically exposed populations and (c) occupationally exposed groups16Go. The LSS cohort of Japanese atomic bomb survivors is unusual among exposed populations in that both genders and a wide range of ages were exposed, comparable with those of a general population8Go. Most medically treated groups are more restricted in the age and gender mix. For example, the International Radiation Study of Cervical Cancer patients (IRSCC), a cohort of women followed up after treatment for cancer of the cervix, were all treated as adults, most above the age of 4021,Go22Go. Organ doses among those treated with radiotherapy tend to be higher than those received by the Japanese atomic bomb survivors, although there are some exceptions, e.g. breast doses in the IRSCC patients22Go. Occupationally exposed groups are also more restricted in their age and gender mix. For example, the cohorts of workers exposed in the nuclear industry23,Go24Go are overwhelmingly male and exposed in adulthood, as are the groups of underground miners25Go. For these reasons, most standard setting bodies5,Go16,Go26,Go27Go use the LSS as the basis for estimates of population cancer risk associated with exposure to low LET radiation. For certain cancer sites and types of radiation exposures, other groups are occasionally used; in particular for high LET ({alpha}-particle) exposure to the lung, underground miners are used25Go, and for breast, bone and liver cancer, certain therapeutically exposed groups are sometimes employed27Go. However, lung cancer risks estimated for the miners by applying those estimated in the LSS in combination with the current ICRP dosimetric model28Go are close to those that can be estimated directly29,Go30Go.

Temporal patterns of risk for radiation-induced cancer
 One of the principal uncertainties that surround the calculation of population cancer risks from epidemiological data results from the fact that few radiation-exposed cohorts have been followed up to extinction. For example, 52 years after the atomic bombings of Hiroshima and Nagasaki, about half of the survivors were still alive8Go. In attempting to calculate lifetime population cancer risks, it is therefore important to predict how risks might vary as a function of time after radiation exposure, in particular for that group for whom the uncertainties in projection of risk to the end of life are most uncertain, namely those who were exposed in childhood.

Analyses of solid cancers in the LSS and other exposed groups have found that the radiation-induced excess risk can be approximately described by a constant relative risk model5Go. The time-constant excess relative risk (ERR) model assumes that if a dose of radiation is administered to a population, then, after some latent period, there is an increase in the cancer rate, the excess rate being proportional to the underlying cancer rate in an unirradiated population. For leukaemia, this model provides an unsatisfactory fit, and consequently a number of other models have been used for this group of malignancies, including one in which the excess cancer rate resulting from exposure is assumed to be constant rather than proportional to the underlying rate, i.e. the time-constant excess absolute risk (EAR) model10Go.

It is well known that for all cancer subtypes (including leukaemia) the ERR diminishes with increasing age at exposure16Go (Figs 1 and 2). For those irradiated in childhood, there is evidence of a reduction in the ERR of solid cancer 25 or more years after exposure8,Go31–GoGo33Go (Fig. 1). Therefore, even for solid cancers, various factors have to be employed to modify the ERR. For many solid cancers, a generalized relative risk model is commonly used, in which the cancer rate t years after exposure for gender s following exposure at age e to a dose D of radiation is given by:

where r0(a, s) is the cancer rate in the absence of irradiation, i.e. the baseline cancer rate, a = t + e is the age at observation (attained age) of the person and F(D) is the function determining the dose dependency of the cancer risk, to be discussed below. The expression {phi}(t, e, s) describes the modification to the ERR, F(D), as a function of time since exposure t, age at exposure e, and gender s.



View larger version (24K):
[in this window]
[in a new window]
  		Fig. 1 The diagram shows the excess relative risk Sv–1 (and 95% CI) for all incident solid tumour cases in Japanese atomic bomb survivors (excluding survivors with >4 Gy shielded kerma) by age at exposure group (top panel: age at exposure < 15 years; bottom panel: 15 ≤ age at exposure < 35years and age at exposure ≥35) as a function of time since exposure (taken from Ref. 51). In particular, this shows a reduction of excess relative risk with increasing age after exposure, and a reduction of excess relative risk with increasing time after exposure for those exposed in childhood (age at exposure < 15).

 


View larger version (16K):
[in this window]
[in a new window]
  		Fig. 2 The diagram shows the excess relative risk Sv–1 (and 95% CI) for all radiogenic leukaemias (acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphocytic leukaemia) in Japanese atomic bomb survivors (excluding survivors with >4 Gy shielded kerma) by age at exposure group and as a function of time since exposure. In particular, this shows a reduction of excess relative risk with increasing age after exposure, and a reduction of excess relative risk with increasing time after exposure.

 

For leukaemia, neither the time-constant EAR model nor the time-constant ERR model fits well (Fig. 2). For reasons largely of ease of interpretation, Preston et al34Go present most of their analyses of the LSS leukaemia incidence dataset using a generalized absolute risk model, in which the cancer rate t years after exposure for gender s following exposure at age e to a dose D of radiation is given by:

The expression {psi}(t, e, s) describes the modification to the EAR, F(D), as a function of time since exposure t, age at exposure e and gender s.

Given appropriate forms of the modifying functions {phi}(t, e, s) and {psi}(t, e, s) of the relative and absolute risk, respectively, equivalently good fits to the leukaemia incidence dataset were achieved using both generalized ERR and generalized EAR models34Go. It is to some extent arbitrary which of these two models one uses. However, as can be seen from Table 3, models with equivalent fit can yield very different risks. The reason for this is that, as noted above, about half the LSS cohort are still alive8Go, so that population risk calculations based on this dataset (used by many scientific committees5,Go16,Go26,Go27Go) crucially depend on extrapolating the current mortality and incidence follow-up of this group to the end of life. Uncertainties due to risk projection are greatest for solid cancers, because the radiation-associated excess risk in the LSS is still increasing8,Go33Go. For leukaemia, the excess risk is reducing over time34Go and most models used predict very few radiation-associated leukaemia deaths or cases from the current follow-up point in the LSS to extinction.

UNSCEAR16Go used a variety of generalized ERR models, linear in dose, for solid cancer risk calculations, including one in which the ERR varied with age at exposure and gender, and one in which the ERR varied with attained age and gender (Table 3). As shown in Table 3, the model with the ERR varying according to attained age yields slightly lower risks than the model in which the ERR varies with age at exposure. For leukaemia, UNSCEAR16Go used a generalized EAR model, linear-quadratic in dose, in which the EAR varied with age at exposure, time since exposure and gender (Table 3).

Forms of cancer dose–response
 It has been customary to model the dose–response function F(D) that appears in Expressions (4) and (5) in fits to biological35Go and epidemiological data16Go by the linear-quadratic expression:

There is significant curvilinearity in the dose–response for leukaemia in the LSS13,Go14,Go36Go, although for solid cancers, apart from non-melanoma skin cancer33,Go37Go and bone cancer38,Go39Go, there is little evidence for anything other than a linear dose–response in the Japanese cohort13–GoGo15Go or in any other group16Go. It should be noted that as well as modifications in effectiveness (per unit dose) relating to alterations in the total dose, there are also possible variations of effectiveness as a result of dose fractionation (the process of splitting a given dose into a number of smaller doses suitably separated in time) and dose-rate35Go. This is not surprising radiobiologically; by administering a given dose at progressively lower dose rates (i.e. giving the same total dose over longer periods of time), or by splitting it into many fractions, the biological system has time to repair the damage, so that the total damage induced will be less35Go. Therefore, although for cancers other than leukaemia there is generally little justification for assuming anything other than a linear dose–response, i.e. ß = 0, it may nevertheless be justifiable to employ a dose and dose-rate effectiveness factor (DDREF) other than 1. The DDREF is the factor by which one divides risks for high dose and high dose-rate exposure to obtain risks for low doses and low dose-rates. The ICRP5Go recommended that a DDREF of 2 be used together with models linear in dose for all cancer sites, on the basis largely of the observations in various epidemiological datasets. UNSCEAR35Go recommended that a DDREF of no more than 3 be used in conjunction with these linear models.

Another form of dose–response, perhaps less commonly used, slightly generalizes Expression (6):

and this has been employed in fits to biological data35Go and epidemiological data13,Go21,Go37,Go40–GoGo42Go. The {alpha}D + ßD2 component represents the effect of (carcinogenic) mutation induction, while the exp({gamma} · D) term represents the effect of cell sterilization or killing. In general, the cell sterilization coefficient g is <0. Essentially, this is saying that there is a competing effect due to cell killing which is greater at higher radiation doses. A dead cell cannot proliferate and become the focus of a malignant clone. Variant forms of the cell-sterilization term exp({gamma} · D), incorporating higher powers of dose D, i.e. exp({gamma} · Dk) for k > 1, are sometimes employed35,Go37Go.

Although it is generally assumed that protraction of radiation dose results in a reduction of effect (i.e. DDREF > 1), largely as a result of the extra time this allows for cellular repair processes to operate, there are biological mechanisms that could result in health effects increasing when dose is protracted (i.e. DDREF < 1). Bystander effects, whereby cells that are not directly exposed to radiation exhibit adverse biological effects, have been observed in a number of experimental systems16Go. The bystander effect implies that the dose–response after broad-beam irradiation could be highly concave at low doses because of saturation of the bystander effect at high doses, so that predictions of low-dose effects obtained by linear extrapolation from data for high-dose exposures would be substantial underestimates. Recently, Brenner et al43Go proposed a model for the bystander effect based on the oncogenic transformation data of Sawant et al44Go and Miller et al45Go for in vitro exposure of C3H 10T1/2 cells to a-particles. Brenner et al43Go discussed evidence from experimental systems that would be consistent with the linear extrapolation of high-dose effects to low doses underestimating oncogenic transformation rates by a factor of between 60 and 3000. However, Little and Wakeford46Go assess the ratio of the lung cancer risk among persons exposed to low (residential) doses of radon daughters to that among persons (underground miners) exposed to high doses of radon daughters to lie in the range 2–4, with an upper 95% confidence limit of about 14, and a lower 95% confidence limit of less than 1. This implies that low dose-rate lung cancer risks associated with a-particle exposure are not seriously underestimated by extrapolation from the high-dose miner data, and that the bystander effect observed in the C3H 10T1/2 cell system cannot play a large part in the process of radon-induced lung carcinogenesis in humans46Go.

Projection of cancer risk across populations
 Associated with the issue of projection of cancer risk over time is that of projection of cancer risk between two populations with differing underlying susceptibilities to cancer. Analogous to the constant relative-risk time projection model is the multiplicative transfer of risks, in which the ratio of the radiation-induced excess cancer rates to the underlying cancer rates in the two populations is assumed to be identical. Similarly, akin to the absolute-risk time projection model is the additive transfer of risks, in which the radiation-induced excess cancer rates in the two populations are assumed to be identical. The data that are available suggest that there is no simple solution to the problem47Go. For example, there are weak indications that the ERRs of stomach cancer following radiation exposure may be more comparable than the EARs in populations with different background stomach cancer rates47Go. Comparison of breast cancer risks observed in the Japanese atomic bomb survivor incidence data and those in various medically exposed populations, many from North America and Europe, where underlying breast cancer rates are higher than in Japan, suggests that ERRs are rather higher in the LSS than those in the medically irradiated groups, but (time- and age-adjusted) EARs are more similar48,Go49Go. The observation that gender differences in solid tumour ERR are generally offset by differences in gender-specific background cancer rates47Go might suggest that EARs are more alike than ERRs. Taken together, these considerations suggest that in various circumstances, relative or absolute transfers of risk between populations may be advocated or, indeed, the use of some sort of hybrid approach such as that employed by Muirhead and Darby50Go and Little et al51Go. Table 3 illustrates the effect of transporting either the absolute risk or the relative risk for solid cancers on the population risk for a UK population. As can be seen, for solid tumours in aggregate the transfer of absolute risk results in slightly lower risks than the transfer of relative risk. However, the differences can be much greater (and in different directions) for specific types of solid tumour.

ERRs in medically exposed groups are generally lower than those in age-, gender- and interval-of-follow-up-matched subsets of the Japanese atomic bomb survivors52,Go53Go. The most striking discrepancies between the ERRs in the medical series and in the LSS were for leukaemia52,Go53Go. The discrepancy between the LSS and radiotherapy ERRs for leukaemia and various other sites can be largely explained by cell-sterilization effects52,Go53Go. This finding is supported by a joint analysis of leukaemia in the LSS34Go, in a group of women treated for cervical cancer21Go, and in a group treated for ankylosing spondylitis41Go, which found evidence of a quadratic-exponential dose–response for all radiogenic leukaemia subtypes, with no significant differences between the dose–response in the LSS and the two medical series42Go.

Radiogenic cancer risks derived from groups of nuclear workers are generally consistent with those obtained from the LSS23,Go24Go. For example Muirhead et al24Go estimate that the ratio of the leukaemia ERR coefficient in the UK nuclear workers to that in the LSS is 1.18 (90% CI <0, 3.73), and the corresponding ratio for all malignant neoplasms excluding lung cancer and leukaemia is 0.89 (90% CI <0, 3.65). The ratio of lung cancer risk coefficients in the LSS and the Colorado Plateau uranium miners is very close to the value suggested by the latest ICRP28Go model of lung dosimetry30Go.

Interaction of radiation-associated cancer risk with chemotherapy
 Factors confounded with radiation dose are present in many treatment regimens in medically exposed groups, and in the most recent cases treated occur as a clinically necessary requirement. The most important confounding factor is chemotherapy at some time before, during, or after radiotherapy. This has recently been reviewed elsewhere52,Go54Go. There is limited quantitative information to assess this interaction, and no marked differences in ERR have been noted between patients receiving and those not receiving adjuvant chemotherapy52,Go54Go. However, radiogenic EARs are higher in some chemotherapy-treated groups than those among patients not so treated54Go.

Interaction of radiation-associated cancer risk with smoking and other lifestyle factors
 There is limited information on interaction of ionizing radiation with lifestyle factors. In particular, few studies of medically-exposed groups have high-quality information on smoking. Inskip et al55Go found that, after adjustment for smoking status, the ERR associated with radiotherapy changed only marginally. Davis et al56Go observed a statistically significant excess risk of lung cancer only among radiation-unexposed patients with an unknown smoking history. The smoking information in both of these studies was limited to knowledge of whether or not the person had ever been a smoker. Much better information on smoking status was collected by van Leeuwen et al57Go, who observed a stronger trend of lung-cancer risk with radiotherapy dose among people who had more than 1 pack-year of cigarette exposure than in those smoking less than this amount; the interaction between the effects of radiation and cigarette smoke on lung-cancer risk was roughly multiplicative. In the LSS smoking and radiation interact additively on the ERR58Go. Analysis of lung cancer in relation to radon daughter and cigarette-smoke exposure in various cohorts of underground miners suggests that the interaction of radon daughters and cigarette smoke is intermediate between additive and multiplicative in the effects on relative risk of lung cancer25,Go30Go, although the quality of the smoking information is poor. Evidence for interaction of ionizing radiation with other lifestyle factors has been reviewed by UNSCEAR16Go.

Interaction of radiation-associated cancer risk with cancer-prone disorders
 There is limited information on interactions of radiotherapy and cancer-prone conditions in relation to second-cancer risk in studies of people treated for cancer, and this has been reviewed elsewhere52,Go54Go. The published data indicate that second-cancer ERR was somewhat lower among patients with a familial cancer syndrome than among those patients without52,Go54Go. Although there are indications of rather lower radiogenic ERRs among people with cancer-prone disorders, the radiogenic EARs can be higher52,Go54Go. As discussed above, the fact that ERRs are lower in people with cancer-prone disorders is consistent with a more general pattern observed in epidemiological data, whereby higher underlying cancer risks are to some extent offset by lower radiogenic cancer ERRs16Go.

Non-cancer late health effects
 There is emerging evidence of excess risks of non-cancer late health effects in the LSS8,Go59Go. In particular, excess radiation-associated mortality due to circulatory, digestive and respiratory diseases has been observed in this cohort8,Go59Go. However, the form of the dose–response is uncertain8,Go59Go, and there is little evidence of elevated non-cancer risks in other exposed groups16Go, so that it may be premature to use these data to estimate low dose risks for a general population.


   Key points for clinical practice
Top
 Abstract
 Introduction
 Types of ionizing radiation,...
 Health effects
 Key points for clinical...
Acknowledgements
 References
 

  • Except in radiotherapy, where deterministic effects may arise, stochastic effects, and particularly cancer in the directly exposed population, are the principal adverse health effects of exposure to ionizing radiation. Most information on cancer risk is derived from the survivors of the Japanese atomic bomb explosions.
  • In general, the radiation-associated excess relative risks among the Japanese atomic bomb survivors are greater than those among medically-exposed individuals, although excess absolute risks can be higher in the medically-exposed groups.
  • There is no evidence of higher radiation-associated excess relative risk among those with cancer-prone disorders, although excess absolute risks can be higher in these cancer-prone groups.
  • Risks among occupationally exposed groups such as nuclear workforces and underground miners are generally consistent with those observed in the Japanese atomic bomb survivors.


   Acknowledgements
Top
 Abstract
 Introduction
 Types of ionizing radiation,...
 Health effects
 Key points for clinical...
 Acknowledgements
References
 
The author is grateful for the detailed and helpful remarks of Dr Richard Wakeford, Dr David Lloyd, Mr Alan Edwards, Dr Monty Charles, Dr E. Janet Tawn, Professor Krishnaswami Sankaranarayanan, Dr Colin Muirhead, Dr Mike Joffe and a referee. This work was funded partially by the European Commission under contract FIGD-CT-2000–0079. This paper makes use of data obtained from the Radiation Effects Research Foundation (RERF) in Hiroshima, Japan. RERF is a private foundation funded equally by the Japanese Ministry of Health and Welfare and the US Department of Energy through the US National Academy of Sciences. The conclusions in this paper are those of the author and do not necessarily reflect the scientific judgement of RERF or its funding agencies.


   References
Top
 Abstract
 Introduction
 Types of ionizing radiation,...
 Health effects
 Key points for clinical...
 Acknowledgements
 References
 

  1. Stevens LG. Injurious effects on the skin. BMJ 1896; 1: 998
  2. Gilchrist TC. A case of dermatitis due to the x rays. Bull Johns Hopkins Hosp 1897; 8(71): 17–22
  3. Frieben A. Demonstration eines Cancroids des rechten Handrückens, das sich nach langdauernder Einwirkung von Röntgenstrahlen bei einem 33 jährigen Mann entwickelt hatte. Fortschr Röntgenstr 1902; 6: 106
  4. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Sources and Effects of Ionizing Radiation. UNSCEAR 2000 Report to the General Assembly, with Scientific Annexes. Volume I: Sources. New York: United Nations, 2000
  5. International Commission on Radiological Protection (ICRP). Publication 60. 1990 Recommendations of the International Commission on Radiological Protection. Ann ICRP 1991; 21(1–3). Oxford: Pergamon
  6. International Commission on Radiation Units and Measurements (ICRU). The Quality Factor in Radiation Protection. ICRU Report 40. Bethesda, MD: ICRU, 1986
  7. National Council on Radiation Protection and Measurements (NCRP). The Relative Biological Effectiveness of Radiations of Different Quality. NCRP Report No. 104. Bethesda, MD: NCRP, 1990
  8. Preston DL, Shimizn Y, Pierce DA, Suyama A, Kabuchi K. Studies of the mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950–1997. Radiat Res 2003; 160: 381–407[CrossRef][ISI][Medline]
  9. Edwards AA, Lloyd DC. Risk from deterministic effects of ionising radiation. Docs NRPB 1996; 7(3): 1–31
  10. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Sources, Effects and Risks of Ionizing Radiation. UNSCEAR 1988 Report to the General Assembly, with Annexes. New York: United Nations, 1988
  11. Otake M, Schull WJ, Lee S. Threshold for radiation-related severe mental retardation in prenatally exposed A-bomb survivors: a re-analysis. Int J Radiat Biol 1996; 70: 755–63[CrossRef][ISI][Medline]
  12. Otake M, Schull WJ. Review: Radiation-related brain damage and growth retardation among the prenatally exposed atomic bomb survivors. Int J Radiat Biol 1998; 74: 159–71[CrossRef][ISI][Medline]
  13. Little MP, Muirhead CR. Evidence for curvilinearity in the cancer incidence dose–response in the Japanese atomic bomb survivors. Int J Radiat Biol 1996; 70: 83–94[CrossRef][ISI][Medline]
  14. Little MP, Muirhead CR. Curvature in the cancer mortality dose response in Japanese atomic bomb survivors: absence of evidence of threshold. Int J Radiat Biol 1998; 74: 471–80[CrossRef][ISI][Medline]
  15. Pierce DA, Preston DL. Radiation-related cancer risks at low doses among atomic bomb survivors. Radiat Res 2000; 154: 178–86[ISI][Medline]
  16. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Sources and Effects of Ionizing Radiation. UNSCEAR 2000 Report to the General Assembly, with Scientific Annexes. Volume II: Effects. New York: United Nations, 2000
  17. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Hereditary Effects of Radiation. UNSCEAR 2001 Report to the General Assembly, with Scientific Annex. New York: United Nations, 2001
  18. Neel JV, Schull WJ, Awa AA et al. The children of parents exposed to atomic bombs: estimates of the genetic doubling dose of radiation for humans. Am J Hum Genet 1990; 46: 1053–72[ISI][Medline]
  19. Dubrova YE, Nesterov VN, Krouchinsky NG et al. Human minisatellite mutation rate after the Chernobyl accident. Nature 1996; 380: 683–6[CrossRef][Medline]
  20. Dubrova YE, Bersimbaev RI, Djansugurova LB et al. Nuclear weapons tests and human germline mutation rate. Science 2002; 295: 1037[Free Full Text]
  21. Boice JD Jr, Blettner M, Kleinerman RA et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 1987; 79: 1295–311[ISI][Medline]
  22. Boice JD Jr, Engholm G, Kleinerman RA et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 1988; 116: 3–55; 127: 118[CrossRef]
  23. Cardis E, Gilbert ES, Carpenter L et al. Effects of low doses and low dose rates of external ionizing radiation: cancer mortality among nuclear industry workers in three countries. Radiat Res 1995; 142: 117–32[ISI][Medline]
  24. Muirhead CR, Goodill AA, Haylock RGE et al. Occupational radiation exposure and mortality: second analysis of the National Registry for Radiation Workers. J Radiol Prot 1999; 19: 3–26[CrossRef][Medline]
  25. US National Academy of Sciences, National Research Council, Committee on Health Risks of Exposure to Radon (BEIR VI). Health Effects of Exposure to Radon. Washington, DC: National Academy Press, 1999
  26. US National Academy of Sciences, National Research Council, Committee on the Biological Effects of Ionizing Radiations, Health Effects of Exposure to Low Levels of Ionizing Radiation (BEIR V). Washington, DC: National Academy Press, 1990
  27. Muirhead CR, Cox R, Stather JW, MacGibbon BH, Edwards AA, Haylock RGE. Estimates of late radiation risks to the UK population. Docs NRPB 1993; 4(4): 15–157
  28. International Commission on Radiological Protection (ICRP). Human Respiratory Tract Model for Radiological Protection. A Report of a Task Group of the International Commission on Radiological Protection. Ann ICRP 1994; 24(1–3): 1–482. Oxford: Pergamon
  29. Birchall A, James AC. Uncertainty analysis of the effective dose per unit exposure from radon progeny and implications for ICRP risk-weighting factors. Radiat Prot Dosim 1994; 53: 133–40[Abstract]
  30. Little MP. Comparisons of lung tumour mortality risk in the Japanese A-bomb survivors and in the Colorado Plateau uranium miners: support for the ICRP lung model. Int J Radiat Biol 2002; 78: 145–63[CrossRef][ISI][Medline]
  31. Little MP, Hawkins MM, Shore RE, Charles MW, Hildreth NG. Time variations in the risk of cancer following irradiation in childhood. Radiat Res 1991; 126: 304–16; 132: 126[CrossRef]
  32. Little MP, de Vathaire F, Charles MW, Hawkins MM, Muirhead CR. Variations with time and age in the risks of solid cancer incidence after radiation exposure in childhood. Stat Med 1998; 17: 1341–55[CrossRef][ISI][Medline]
  33. Thompson DE, Mabuchi K, Ron E et al. Cancer incidence in atomic bomb survivors. Part II: solid tumors, 1958–1987. Radiat Res 1994; 137: S17–S67; 139: 129
  34. Preston DL, Kusumi S, Tomonaga M et al. Cancer incidence in atomic bomb survivors. Part III: leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res 1994; 137: S68–S97; 139: 129
  35. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Sources and Effects of Ionizing Radiation. UNSCEAR 1993 Report to the General Assembly, with Scientific Annexes. New York: United Nations, 1993
  36. Pierce DA, Vaeth M. The shape of the cancer mortality dose–response curve for the A-bomb survivors. Radiat Res 1991; 126: 36–42[CrossRef][ISI][Medline]
  37. Little MP, Charles MW. The risk of non-melanoma skin cancer incidence in the Japanese atomic bomb survivors. Int J Radiat Biol 1997; 71: 589–602[CrossRef][ISI][Medline]
  38. Rowland RE, Stehney AF, Lucas HF Jr. Dose–response relationships for female radium dial workers. Radiat Res 1978; 76: 368–83[ISI][Medline]
  39. Thomas RG. The US radium luminisers: a case for a policy of ‘below regulatory concern’. J Radiol Prot 1994; 14: 141–53
  40. Thomas DC, Blettner M, Day NE. Use of external rates in nested case-control studies with application to the International Radiation Study of Cervical Cancer patients. Biometrics 1992; 48: 781–94[CrossRef][ISI][Medline]
  41. Weiss HA, Darby SC, Fearn T, Doll R. Leukemia mortality after X-ray treatment for ankylosing spondylitis. Radiat Res 1995; 142: 1–11[ISI][Medline]
  42. Little MP, Weiss HA, Boice JD Jr, Darby SC, Day NE, Muirhead CR. Risks of leukemia in Japanese atomic bomb survivors, in women treated for cervical cancer, and in patients treated for ankylosing spondylitis. Radiat Res 1999; 152: 280–92; 153: 243[CrossRef]
  43. Brenner DJ, Little JB, Sachs RK. The bystander effect in radiation oncogenesis: II. A quantitative model. Radiat Res 2001; 155: 402–8[CrossRef][ISI][Medline]
  44. Sawant SG, Randers-Pehrson G, Geard CR, Brenner DJ, Hall EJ. The bystander effect in radiation oncogenesis: I. Transformation in C3H 10T1/2 cells in vitro can be initiated in the unirradiated neighbors of irradiated cells. Radiat Res 2001; 155: 397–401[ISI][Medline]
  45. Miller RC, Randers-Pehrson G, Geard CR, Hall EJ, Brenner DJ. The oncogenic transforming potential of the passage of single a particles through mammalian cell nuclei. Proc Natl Acad Sci USA 1999; 96: 19–22[Abstract/Free Full Text]
  46. Little MP, Wakeford R. The bystander effect in C3H 10T1/2 cells and radon-induced lung cancer. Radiat Res 2001; 156: 695–9[CrossRef][ISI][Medline]
  47. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR). Sources and Effects of Ionizing Radiation. UNSCEAR 1994 Report to the General Assembly, with Scientific Annexes. New York: United Nations, 1994
  48. Little MP, Boice JD Jr. Comparison of breast cancer incidence in the Massachusetts tuberculosis fluoroscopy cohort and in the Japanese atomic bomb survivors. Radiat Res 1999; 151: 218–24[ISI][Medline]
  49. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 2002; 158: 220–35; 666[CrossRef][ISI][Medline]
  50. Muirhead CR, Darby SC. Modelling the relative and absolute risks of radiation-induced cancers. J R Stat Soc A 1987; 150: 83–118
  51. Little MP, Muirhead CR, Charles MW. Describing time and age variations in the risk of radiation-induced solid tumour incidence in the Japanese atomic bomb survivors using generalized relative and absolute risk models. Stat Med 1999; 18: 17–33[CrossRef][ISI][Medline]
  52. Little MP, Muirhead CR, Haylock RGE, Thomas JM. Relative risks of radiation-associated cancer: comparison of second cancer in therapeutically irradiated populations with the Japanese atomic bomb survivors. Radiat Environ Biophys 1999; 38: 267–83[CrossRef][ISI][Medline]
  53. Little MP. Comparison of the risks of cancer incidence and mortality following radiation therapy for benign and malignant disease with the cancer risks observed in the Japanese A-bomb survivors. Int J Radiat Biol 2001; 77: 431–64; 745–60[CrossRef][ISI][Medline]
  54. Little MP. Cancer after exposure to radiation in the course of treatment for benign and malignant disease. Lancet Oncol 2001; 2: 212–20[CrossRef][Medline]
  55. Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 1994; 86: 983–8[Abstract/Free Full Text]
  56. Davis FG, Boice JD Jr, Hrubec Z, Monson RR. Cancer mortality in a radiation-exposed cohort of Massachusetts tuberculosis patients. Cancer Res 1989; 49: 6130–6[Abstract/Free Full Text]
  57. van Leeuwen FE, Klokman WJ, Stovall M et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 1995; 87: 1530–7[Abstract/Free Full Text]
  58. Pierce DA, Sharp GB, Mabuchi K. Joint effects of radiation and smoking on lung cancer risk among atomic bomb survivors. Radiat Res 2003; 159: 511–520[ISI][Medline]
  59. Wong FL, Yamada M, Sasaki H, Kodama K, Akiba S, Shimaoka K, Hosoda Y. Noncancer disease incidence in the atomic bomb survivors: 1958–1986. Radiat Res 1993; 135: 418–430[ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Br. J. Radiol.Home page
M Jawad, G Giotopoulos, C Cole, and M Plumb
Target cell frequency is a genetically determined risk factor in radiation leukaemogenesis
Br. J. Radiol., September 1, 2007; 80(Special_Issue_1): S56 - S62.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
I. Shuryak, R. K. Sachs, L. Hlatky, M. P. Little, P. Hahnfeldt, and D. J. Brenner
Radiation-Induced Leukemia at Doses Relevant to Radiation Therapy: Modeling Mechanisms and Estimating Risks
J Natl Cancer Inst, December 20, 2006; 98(24): 1794 - 1806.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive